New Oral Formulation and in Vitro Evaluation of Docetaxel-Loaded Nanomicelles

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2016 Sep 23

PMID 27657038

Citations 7

Authors

Atefeh Hekmat

Hossein Attar

Ali Akbar Seyf Kordi

Maryam Iman

Mahmoud Reza Jaafari

Affiliations

Soon will be listed here.

Abstract

Intravenous administration of Taxotere (a commercial form of docetaxel, DTX) leads to many problems such as hypersensitivity, hemolysis, cutaneous allergy, and patient refusal due to its prolonged injection. The oral absorption of DTX is very low due to its hydrophobic nature. The purpose of this study was to prepare and carry out an in vitro evaluation of DTX-loaded nanomicelles for oral administration in order to increase the oral delivery of DTX. Studied formulations were prepared with the two surfactants Tween 20 and Tween 80 and were characterized for their particle size, zeta potential, stability, encapsulation efficiency, stability studies in gastric fluid and intestinal fluid, toxicity studies in C26 colon carcinoma cell line, and cellular uptake. The prepared nanomicelles with particle size of around 14 nm and encapsulation efficiency of 99% were stable in gastric fluid and intestinal fluid for at least 6 h and IC50 decreased significantly after 72 h exposure compared to that of Taxotere. Nanomicelles increased the water solubility of DTX more than 1500 times (10 mg/mL in nanomicelles compared to 6 µg/mL in water). Results of this study reveal that the new formulation of DTX could be used for the oral delivery of DTX and merits further investigation.

Citing Articles

Docetaxel Micelles: A New Formulation to Diminish Hypersensitivity Reactions.

Xiang L, Wang H, Liu J, Shen Y, Hu Y, Che W Pharmaceutics. 2025; 17(2).

PMID: 40006551 PMC: 11859302. DOI: 10.3390/pharmaceutics17020184.

Management of Brain Cancer and Neurodegenerative Disorders with Polymer-Based Nanoparticles as a Biocompatible Platform.

Bazi Alahri M, Jibril Ibrahim A, Barani M, Arkaban H, Shadman S, Salarpour S Molecules. 2023; 28(2).

PMID: 36677899 PMC: 9864049. DOI: 10.3390/molecules28020841.

Nanocrystal-Loaded Micelles for the Enhanced In Vivo Circulation of Docetaxel.

Cheng M, Liu Q, Gan T, Fang Y, Yue P, Sun Y Molecules. 2021; 26(15).

PMID: 34361634 PMC: 8348076. DOI: 10.3390/molecules26154481.

Chitosan-Coated Flexible Liposomes Magnify the Anticancer Activity and Bioavailability of Docetaxel: Impact on Composition.

Alshraim M, Sangi S, Harisa G, Alomrani A, Yusuf O, Badran M Molecules. 2019; 24(2).

PMID: 30641899 PMC: 6359228. DOI: 10.3390/molecules24020250.

In situ misemgel as a multifunctional dual-absorption platform for nasal delivery of raloxifene hydrochloride: formulation, characterization, and in vivo performance.

Ahmed O, Badr-Eldin S Int J Nanomedicine. 2018; 13:6325-6335.

PMID: 30349253 PMC: 6188068. DOI: 10.2147/IJN.S181587.

References

Dintaman J, Silverman J . Inhibition of P-glycoprotein by D-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS). Pharm Res. 1999; 16(10):1550-6. DOI: 10.1023/a:1015000503629. View

Cavalli R, Caputo O, Gasco M . Preparation and characterization of solid lipid nanospheres containing paclitaxel. Eur J Pharm Sci. 2000; 10(4):305-9. DOI: 10.1016/s0928-0987(00)00081-6. View

Muller R, Mader K, Gohla S . Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm. 2000; 50(1):161-77. DOI: 10.1016/s0939-6411(00)00087-4. View

Kaunitz J, Akiba Y . Luminal acid elicits a protective duodenal mucosal response. Keio J Med. 2002; 51(1):29-35. DOI: 10.2302/kjm.51.29. View

Chin D, Lum B, Sikic B . Rapid determination of PEGylated liposomal doxorubicin and its major metabolite in human plasma by ultraviolet-visible high-performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci. 2002; 779(2):259-69. PMC: 4198311. DOI: 10.1016/s1570-0232(02)00395-1. View

Mu L, Teo M, Ning H, Tan C, Feng S . Novel powder formulations for controlled delivery of poorly soluble anticancer drug: application and investigation of TPGS and PEG in spray-dried particulate system. J Control Release. 2005; 103(3):565-75. DOI: 10.1016/j.jconrel.2004.12.023. View

Khalid M, Simard P, Hoarau D, Dragomir A, Leroux J . Long circulating poly(ethylene glycol)-decorated lipid nanocapsules deliver docetaxel to solid tumors. Pharm Res. 2006; 23(4):752-8. DOI: 10.1007/s11095-006-9662-5. View

Lee M, Lim S, Kim C . Preparation, characterization and in vitro cytotoxicity of paclitaxel-loaded sterically stabilized solid lipid nanoparticles. Biomaterials. 2007; 28(12):2137-46. DOI: 10.1016/j.biomaterials.2007.01.014. View

Winther D, Saunte D, Knap M, Haahr V, Jensen A . Nail changes due to docetaxel--a neglected side effect and nuisance for the patient. Support Care Cancer. 2007; 15(10):1191-7. DOI: 10.1007/s00520-007-0232-0. View

10.

Nagayama S, Ogawara K, Fukuoka Y, Higaki K, Kimura T . Time-dependent changes in opsonin amount associated on nanoparticles alter their hepatic uptake characteristics. Int J Pharm. 2007; 342(1-2):215-21. DOI: 10.1016/j.ijpharm.2007.04.036. View

11.

Cuppone F, Bria E, Carlini P, Milella M, Felici A, Sperduti I . Taxanes as primary chemotherapy for early breast cancer: meta-analysis of randomized trials. Cancer. 2008; 113(2):238-46. DOI: 10.1002/cncr.23544. View

12.

Baker J, Ajani J, Scotte F, Winther D, Martin M, Aapro M . Docetaxel-related side effects and their management. Eur J Oncol Nurs. 2008; 12(3):253-68. DOI: 10.1016/j.ejon.2008.03.006. View

13.

Sissung T, Baum C, Deeken J, Price D, Aragon-Ching J, Steinberg S . ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel. Clin Cancer Res. 2008; 14(14):4543-9. PMC: 2723795. DOI: 10.1158/1078-0432.CCR-07-4230. View

14.

Xu Z, Chen L, Gu W, Gao Y, Lin L, Zhang Z . The performance of docetaxel-loaded solid lipid nanoparticles targeted to hepatocellular carcinoma. Biomaterials. 2008; 30(2):226-32. DOI: 10.1016/j.biomaterials.2008.09.014. View

15.

Yang Y, Wang J, Zhang X, Lu W, Zhang Q . A novel mixed micelle gel with thermo-sensitive property for the local delivery of docetaxel. J Control Release. 2009; 135(2):175-82. DOI: 10.1016/j.jconrel.2009.01.007. View

16.

Yan F, Zhang C, Zheng Y, Mei L, Tang L, Song C . The effect of poloxamer 188 on nanoparticle morphology, size, cancer cell uptake, and cytotoxicity. Nanomedicine. 2009; 6(1):170-8. DOI: 10.1016/j.nano.2009.05.004. View

17.

Yanasarn N, Sloat B, Cui Z . Nanoparticles engineered from lecithin-in-water emulsions as a potential delivery system for docetaxel. Int J Pharm. 2009; 379(1):174-80. PMC: 2736872. DOI: 10.1016/j.ijpharm.2009.06.004. View

18.

Yin Y, Cui F, Mu C, Choi M, Kim J, Chung S . Docetaxel microemulsion for enhanced oral bioavailability: preparation and in vitro and in vivo evaluation. J Control Release. 2009; 140(2):86-94. DOI: 10.1016/j.jconrel.2009.08.015. View

19.

Lee E, Kim H, Lee I, Jon S . In vivo antitumor effects of chitosan-conjugated docetaxel after oral administration. J Control Release. 2009; 140(2):79-85. DOI: 10.1016/j.jconrel.2009.08.014. View

20.

Kedar U, Phutane P, Shidhaye S, Kadam V . Advances in polymeric micelles for drug delivery and tumor targeting. Nanomedicine. 2010; 6(6):714-29. DOI: 10.1016/j.nano.2010.05.005. View